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A Comparison of Two Stereotactic Body Radiation
Fractionation Schedules for Medically Inoperable Stage I
Non-small Cell Lung Cancer
The Cleveland Clinic Experience
Kevin L. Stephans, MD,* Toufik Djemil, PhD,* Chandana A. Reddy, MS,* Stephen M. Gajdos, MS,*
Matthew Kolar, MS,* David Mason, MD,† Sudish Murthy, MD,† Thomas W. Rice, MD,†
Peter Mazzone, MD,‡ Michael Machuzak, MD,‡ Tarek Mekhail, MD,§
and Gregory M. M. Videtic, MD, CM, FRCPC*
Purpose: To assess the impact of fractionation upon tumor control
and toxicity in medically inoperable early stage lung cancer patients
treated with stereotactic body radiotherapy.
Methods: We reviewed 94 consecutive stereotactic body radiother-
apy treatments (86 patients) with medically inoperable stage I
non-small cell lung cancer receiving either 50 Gy in five fractions
(n  56) or 60 Gy in three fractions (n  38) from October 2003 to
August 2007. Institutional practice was 10 Gy  5 before March 1,
2006, when it changed to 20 Gy  3 to conform to Radiation
Therapy Oncology Group 0236 unless otherwise dictated clinically.
Results:Median age was 73 years and median Karnofsky performance
status 80. A total of 69 lesions were T1, 24 were T2 lung cancer.
Median follow-up was 15.3 months. For the 50- and 60-Gy cohorts at
1 year, local control was 97.3% versus 100%, nodal failure 7.3% versus
3.4%, distant metastasis rate 21.8% versus 29.5%, and overall survival
83.1% versus 76.9% (p  0.68, 0.54, 0.56, and 0.54, respectively).
There was no difference in overall survival for patients with histo-
logic (n  61) compared with radiographic (n  33) diagnosis.
There was no impact of fractionation in the subset of T2 tumors. We
observed two cases (2.2%) of clinical grade 2 pneumonitis. Mild late
chest wall toxicity (grade 1 or 2) was seen in nine patients (10%) at
a median of 8.4 months after treatment and was more common in the
60-Gy group (7 of 38 [18%] versus 2 of 56 [4%], p  0.028).
Conclusions: Local control, overall survival, nodal failure, and
distant failure were not affected by fractionation. Chest wall toxicity
was more common with 60-Gy group.
Key Words:Medically inoperable, Stage I lung cancer, Stereotactic
body radiotherapy, Dose/fractionation.
(J Thorac Oncol. 2009;4: 976–982)
Stereotactic body radiotherapy (SBRT) is increasingly usedin the management of early stage non-small cell lung
cancer (NSCLC), particularly, for patients in whom medical
comorbidities preclude surgical resection. Prospective trials
have demonstrated the feasibility, safety, and efficacy of this
treatment modality yielding high rates of local control and
overall survival with remarkably little toxicity in what is
otherwise a fragile population.1–13
Evidence exists for a dose-response relationship with
standard fractionated radiation in stage I NSCLC.14,15 SBRT
delivers a substantially higher biologically effective dose
(BED). Despite significant evidence documenting efficacy,
data on dose-response relationships for SBRT are limited. In
a phase I dose escalation at the University of Indiana using
three fractions, all local failures occurred in patients receiving
less than 18 Gy per fraction.4 In the largest series to date,
Onishi et al.9 reports that for 257 patients, BEDs of 100
Gy10 were associated with improved local control and overall
survival. In contrast, a review of 138 patients treated in
Nordic countries to a dose range of 65 to 205 Gy in 2 Gy per
fraction equivalents demonstrated no correlation between
prescription or peripheral dose and local control.1 Further-
more, biologic modeling of SBRT is still in evolution,16–18
and studies with large varieties of dosing schedules likely
face larger uncertainties in comparing treatment regimens.
SBRT is associated with very little toxicity. Radiation
pneumonitis occurs in approximately 1% of properly selected
patients,3–5,8–10,19 and reports of other toxicities including
chest wall and esophagitis are limited.3,4,8–10,20,21 Correlation
of dose to toxicity is not yet reported. Our data offers a
unique advantage of being composed of only two fraction-
ation schedules, limiting uncertainties with modeling many
schedules simultaneously. The purpose of this report is to
Departments of *Radiation Oncology; †Thoracic Surgery; ‡Pulmonary
Medicine; and §Hematology and Medical Oncology, Cleveland
Clinic, Cleveland, Ohio.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Gregory M. M. Videtic, MD, Department of
Radiation Oncology/T28, Cleveland Clinic Foundation, 9500 Euclid
Avenue, Cleveland, OH 44195. E-mail: videtig@ccf.org
Presented in part at the 50th annual meeting of ASTRO in Boston, MA,
September 21–25, 2008.
Copyright © 2009 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/09/0408-0976
Journal of Thoracic Oncology • Volume 4, Number 8, August 2009976
investigate the differences in local control and toxicity of two
SBRT regimens with substantially different BEDs (50 Gy in
five fractions, BED  100 Gy10 compared with 60 Gy in
three fractions, BED  180 Gy10).
PATIENTS AND METHODS
Patient and Tumor Characteristics
All data were collected from an institutional review
board approved registry. Eighty-six patients with 94 lesions
(three synchronous, five metachronous) were treated between
February 2004 and August 2007 with either 50 Gy in five
fractions (n  51) or 60 Gy in three fractions (n  35) for
American Joint Committee on Cancer T1A or T1B lung
cancer. All patients were deemed medically inoperable by
multidisciplinary evaluation. Pulmonary causes for inoper-
ability accounted for 69, cardiac for 15, vascular for six, and
multiple causes for four lesions (breakdown by fractionation
in Table 1). Evaluation included history and physical exam-
ination, contrast-enhanced computed tomography of the
chest, [18F]fluorodeoxyglucose positron emission tomogra-
phy (PET), pulmonary function testing, and biopsy unless
medically contraindicated. Patients without histologic diag-
nosis were treated by radiographic criteria (enlarging lesion on
serial CT with a positive PET or increasing standard uptake
value [SUV] on serial PET). Initial follow-up was 6 to 8 weeks
after SBRT with same-day pulmonary function tests (PFTs) and
chest CT. Thereafter, routine follow-up was every 3 months with
CT imaging at each visit and PFTs twice yearly.
Toxicity was assessed according to the Common Termi-
nology Criteria for Adverse Events version 3.0. Chest wall
toxicity was specifically scored by the “pain” category detailed
within that schema (grade 1, mild pain, no need for narcotics;
grade 2, moderate pain, narcotics indicated; grade 3, severe pain;
pain or treatment interferes with activities of daily living; and grade
4, severe pain, disabling). Asymptomatic fractures were not scored.
Local failure was defined as progressive and increasing
CT scan abnormalities confirmed by progressive and incre-
mental increases in a lesion’s SUVs on serial PET imaging,
with or without biopsy. Nodal failure was defined as radio-
graphic (PET or CT) progression in the hilum or mediasti-
num. Distant failure was defined as the presence of distant
metastases on clinical examination or imaging. Local, nodal,
and distant failure were measured by lesion, whereas survival
was calculated by patient from time of first treatment.
Treatment Procedure
Patients were simulated supine in a vacuum bag restric-
tion system (Bodyfix, Elekta Inc., Stockholm, Sweden). An
abdominal compression device was applied to reduce respiratory
movement and adjusted under fluoroscopy to minimize motion.
A planning axial CT scan (3 mm slice thickness) was taken
during quiet breathing, full inspiration, and full expiration. Gross
tumor volume (GTV) was delineated on each respiratory study
using the “lung window” setting. For patients receiving 50 Gy,
planning target volumes (PTV) was defined as a 5-mm three-
dimensional expansion of an internal target volume created by
fusion of the GTVs on the three breathing studies. For patients
receiving 60 Gy, PTV was defined per Radiation Therapy
Oncology Group (RTOG) 0236 as a 5-mm axial and
10-mm craniocaudal expansion of the GTV. Critical struc-
tures including lungs, spinal cord, heart, brachial plexus,
and esophagus were outlined, and doses to these structures
limited according to accepted standards.
Lesions before March 2006 (n 46) were treated to 50
Gy in five fractions over 5 consecutive days modeled on the
principles of Uematsu et al.11 In March 2006, RTOG 0236
planning criteria were adopted, and a prescription of 60 Gy in
three fractions was delivered during an 8 to 14 day interval.22
Patients with a central tumor lying within 2 cm of the
tracheobronchial tree were treated with a prescription of 50
Gy in five fractions even after March 2006. Six patients with
large PTV directly adjacent to critical structures were treated
to 50 Gy in 10 fractions and are excluded from this report.
Treatment plans were generated by BrainScan 5.31
(BrainLAB, Feldkirchen, Germany) planning software refer-
enced to the free-breathing study. Patients were treated on a
Novalis (BrainLAB, Feldkirchen, Germany) machine using
orthogonal films and the ExacTrac (BrainLAB, Feldkirchen,
Germany) stereotactic body system for positioning. Patients
treated to 50 Gy were typically planned using seven-field
noncoplanar intensity modulated radiation therapy with het-




20 Gy  3
(n  38)
10 Gy  5
(n  56)
Age 74 (48–89) 72.5 (49–89) 0.214
KPS 80 (50–90) 70 (40–90) 0.139
Gender: female (%) 61 48 0.240
Stage
T1, n  69 (%) 27 (71.0) 42 (75.0) 0.671
T2, n  25 (%) 11 (29.0) 14 (25.0)
Greatest lesion diameter (cm) 2.35 (1.1–4.0) 2.2 (0.8–6.0) 0.434
Histology
Squamous (%) 12 (31.6) 20 (35.7)
Adenocarcinoma (%) 6 (15.8) 9 (16.1)
PD/other (%) 7 (18.4) 7 (12.5)
No tissue diagnosis (%) 13 (34.2) 20 (35.7)
Smoking history (pack-years) 53 (0–140) 50 (0–150) 0.365
Active smoking: yes (%) 31.6 21.4 0.268
Hemoglobin 13.8 (8.8–16.2) 13.1 (8.8–15.6) 0.414
FEV1 (liter) 1.10 (0.46–2.72) 1.22 (0.41–2.71) 0.442
FEV1 (as % of predicted) 50 (18–138) 48 (15–121) 0.883
DLCO (as % of predicted) 55 (22–143) 57 (14–90) 0.555
Reason for inoperability
Pulmonary (%) 28 (74) 41 (73)
Cardiac (%) 7 (18) 8 (14)
Other/multiple (%) 3 (8) 7 (13)
COPDa (%) 89 86
Congestive heart failureb (%) 24 27
a FEV1/FVC 0.7 and symptomatic.
b Framingham criteria.34
COPD, chronic obstructive pulmonary disease; PD, poorly differentiated; KPS,
Karnofsky performance status; DLCO, diffusion capacity of carbon monoxide; FEV1,
forced expiratory volume in 1 second; FVC, forced vital capacity.
Journal of Thoracic Oncology • Volume 4, Number 8, August 2009 A Comparison of SBRT
Copyright © 2009 by the International Association for the Study of Lung Cancer 977
erogeneity corrections prescribed to the 97 to 100% isodose
line. Patients treated to 60 Gy were typically planned using
three or more dynamic arcs without heterogeneity corrections
prescribed to the 81 to 90% isodose line (as allowed by
RTOG 0236). For the purpose of uniformly reporting dosi-
metric characteristics in this study, all plans were recalculated
with heterogeneity corrections enabled and the same number
of monitor units as delivered at treatment. All beams used
6-MV photons exclusively.
Statistical Analysis
The primary outcomes were local control and survival,
which were measured from the initiation of SBRT until death
or last patient contact. Patient characteristics were compared
using the Mann-Whitney U test and 2 test. Local, nodal, and
distant control and survival probability were illustrated using
the Kaplan-Meier curves, and the log-rank test was used to
determine whether a statistically significant difference was
present between patient groups. Univariate and multivariate
analysis for overall survival were performed using Cox Pro-
portional Hazards regression. Correlations involving chest
wall toxicity were examined with the Fisher’s exact test and
the Mann-Whitney U test. Statistical analyses were per-
formed using StatView 5.0 (SAS Institute, Cary, NC), and a
p value less than 0.05 was considered statistically significant.
RESULTS
Ninety-four lesions were treated with 60 Gy in three
fractions (n  38) or 50 Gy in five fractions (n  56). There
were no significant differences in baseline patient character-
istics between the fractionation groups (Table 1). Of note,
35% of patients had no formal tissue diagnosis and were
treated based on progressive changes in CT and PET criteria.
Median follow-up was 15.3 months (range, 1.9–47.6
months). Follow-up was longer for the 50-Gy group (19.8
months [range, 1.9–47.6 months]) compared with the 60-Gy
group (9.5 months [range, 2.1–19.5 months; p  0.0001]),
due to the longer period over which the 50-Gy treatments
have been employed. Dosimetric properties of treatment by
fractionation scheme are reported in Table 2.
Local control for all patients was 100% at 6 months,
98.2% at 12 months, and 95.3% at 18 months. Only two local
failures occurred, both in the 50-Gy arm: one at 10 months (1.4
cm squamous cell carcinoma in a lung transplant patient) and
one at 15 months (2.5 cm squamous cell carcinoma) from the
end of treatment. Twelve month actuarial local control was
97.3% for the 50 Gy treatment and 100% for those receiving 60
Gy, with no significant difference in the actuarial rate of local
control between fractionation regimens (p  0.536, Figure 1).
Nodal failure occurred in seven patients, and freedom
from nodal failure at 6, 12, and 18 months was 96.0, 94.0, and
90.7% for all patients. Freedom from nodal failure at 12 months
was 92.7% for patients receiving 50 Gy and 96.6% for those
receiving 60 Gy. There was no difference in actuarial rates of
freedom from nodal failure by the fractionation regimen (p 
0.557, Figure 2). Age, Karnofsky performance status (KPS), sex,
smoking history, active smoking, greatest lesion dimension, and
hemoglobin level were tested as univariate predictors of nodal
metastasis, and only KPS was found to be significant with a
p value of 0.0389; however, the relative risk was minimally
elevated at 1.072.
Distant metastasis occurred in 19 patients, and freedom
from distant metastasis at 6, 12, and 18 months was 97.3%,
75.5% and 67.1% for all patients. Freedom from distant metas-
tasis at 12 months was 78.2% for patients receiving 50 Gy and
70.5% for those receiving 60 Gy. There was no difference in the
actuarial rates of distant metastasis by fractionation regimen
(p  0.543, Figure 3). Age, KPS, sex, smoking history, active
smoking, greatest lesion dimension, and hemoglobin level were
tested as univariate predictors of distant metastasis, and only
KPS was found to be significant with a p value of 0.0047;
however, the relative risk was minimally elevated at 1.053.
At the time of analysis, 25 patients had died and overall
survival at 6, 12, and 18 months was 92.6, 80.9, and 75.3%
for all patients. One-year overall survival was 83.1% for
patients receiving 50 Gy, and 76.9% for those receiving 60
Gy. There was no difference in actuarial rates of overall
survival by fractionation regimen (p  0.680, Figure 4). There
was no difference in the survival of patients having histo-
logic confirmation of malignancy compared with those
FIGURE 1. Local recurrence-free survival.




20 Gy  3
(n  38)
10 Gy  5
(n  56)
GTV volume (ml) 9.0 (1.2–66) 7.0 (0.4–87) 0.621
PTV volume (ml) 39.9 (11–140) 30.4 (3.7–137) 0.257
Max PTV dimension (cm) 4.8 (2.8–7.9) 4.6 (2.1–7.4) 0.356
Prescription isodose 89% (81–90) 100% (97–100) 0.0001
Heterogeneity (MD/PD) 1.31 (1.1–1.61) 1.11 (1.04–1.37) 0.0001
Conformality (PIV/TV) 1.48 (1.13–2.28) 1.41 (1.12–1.9) 0.552
Lung V5 (ml) 536.0 632.5 0.14
Lung V20 (ml) 165.6 126.98 0.140
Lung V50 (ml) 41.4 27.1 0.0072
GTV, gross tumor volume; PTV, planning target volumes; MD, maximum dose;
PD, prescription dose; PIV, prescription isodose volume; TV, target volume.
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treated with radiographic diagnosis, p  0.37 (Figure 5).
There was no difference in the survival for the subset of T1 tumors
treated with 50 Gy versus 60 Gy (p  0.72) or T2 tumors treated
with 50 Gy versus 60 Gy, p  0.31 (Figure 6).
Univariate analysis of overall survival tested age, KPS,
sex, smoking history, active smoking, greatest lesion dimen-
sion, American Joint Committee on Cancer T-stage, pretreat-
ment hemoglobin, and fractionation scheme as potential cor-
relates. Females (p  0.0322, relative risk (RR) 0.397),
greater smoking history (p  0.0268, RR 1.013), greatest
lesion dimension (p  0.0102, RR 1.547), and T1 stage (p 
0.0025, RR 0.295) were significantly associated with survival
FIGURE 2. Nodal metastases-free survival.
FIGURE 3. Distant metastases-free survival.
FIGURE 4. Overall survival.
FIGURE 5. Overall survival by availability of histologic diagnosis.
FIGURE 6. Overall survival by stage and fraction size.
TABLE 3. Overall Survival Analysis
Characteristics p RR
Univariate
Greater age 0.0616 1.045
Gender (female) 0.0322 0.397
Greater smoking (pack-years) 0.0268 1.013
Greater lesion dimension (cm) 0.0102 1.547
Multivariate
Gender (female) 0.1266 0.511
Greater smoking (pack-years) 0.0219 1.013
Greater lesion dimension (cm) 0.0093 1.651
RR, relative risk.
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(Table 3). Age (p  0.0616, RR 1.045) trended toward
significance. On multivariate analysis, sex was no longer a
significant predictor of survival (p  0.127), whereas smok-
ing history (p  0.0219, RR 1.013) and greatest lesion
dimension (p  0.0093, RR 1.651) remained significant.
Two patients experienced grade 2 (requiring oral ste-
roids) radiation pneumonitis (one in each fractionation group)
during the follow-up period. There were no cases of grade 3
(requiring new or increased supplemental oxygen) radiation
pneumonitis. There were no differences in PFT changes by
fractionation group (p 0.61 for forced expiratory volume in
1 second and p  0.69 for diffusion capacity of carbon
monoxide). Grade 1 or 2 chest wall toxicity was seen in nine
patients (9.6% of treatments) at a median of 8.4 months after
treatment. Patients with toxicity had a median chest wall V30
of 58 ml (mean 68 ml, range, 25–126 ml), median chest wall
V60 of 9.4 ml (mean 12.3 ml, range, 1.3–29.7 ml), and
median maximum chest wall point dose of 75.6 Gy (mean
76.8 Gy, range 67.5–84.9 Gy). Chest wall toxicity was more
common in the 60-Gy group (7 of 38, 18%) compared with
the 50-Gy group (2 of 56, 4%, p  0.028). This difference
persisted when central lesions were excluded (7 of 38 versus
2 of 49, p  0.039). Age was not associated with toxicity.
Median greatest lesion dimension in patients with toxicity
was 2.8 compared with 2.2 cm in those without (p 0.0544).
DISCUSSION
We found no difference in local, nodal, or distant
control and in overall survival with a median follow-up of
15.3 months for patients treated to 50 Gy compared with 60
Gy. Although no significant difference in control or outcome
was noted, patients treated to 60 Gy were substantially more
likely to express late chest wall toxicity.
Our clinical experience has offered a unique opportu-
nity to compare the efficacy and toxicity of two common
SBRT delivery schedules. Although patients were not ran-
domized between regimens, patient characteristics were sim-
ilar between groups. We have seen only two local failures.
Although both failures occurred in patients receiving 50 Gy,
this group also had a longer follow-up, and the actuarial rates
of local failure were not significantly different. The 9.5-
months (range, 2.1–19.5 months) follow-up in the 60 Gy
group requires further follow-up to substantiate longer term
local control in this group; however, the biologic dose is
substantially higher than for the 50 Gy group, and we would
not expect local control to be worse for patients receiving 60
Gy unless factors aside from dose are driving this. The
18-month failure free rate for the 50-Gy group (BED 100
Gy10), 95.3% is comparable with that achieved in other
series,1,2,4–13 even those employing higher BEDs. If the
similarity in local control between these two fractionation
schedules persists with longer follow-up, 50 Gy in five
fractions may approach or attain the plateau of the dose-
response curve.
The lack of a clear dose-response relationship beyond
BED 100 Gy10 is consistent with prior published reports. In
the largest series to date, Onishi et al.9,23 describes a multi-
institutional Japanese experience with 257 patients treated at
14 institutions with BEDs ranging from 57 to 180 Gy10. He
notes a dramatic reduction in local failure rates with treat-
ments of BED 100 Gy10, 8.4% versus 42.9% (p  0.001),
but no further gains in local control were associated with
BEDs of 120 Gy10 or 140 Gy10. In contrast, a review of
138 patients pooled from five Nordic centers did not identify
a dose-response relationship over a wide range of fraction-
ation regimens.1 Of interest is the fact that in the Nordic
patients’ dose was prescribed to the PTV periphery, whereas
in the Japanese patients, prescriptions were to isocenter. The
authors state that the dose to the central parts of the PTV was
generally 140 to 150% of the specified dose. The lowest BED
prescription given in this study was 30 Gy in three fractions.
Multiplying this by 140% results in an estimated isocenter
dose of 42 Gy in three fractions. Using the linear quadratic
formula without correction for treatment time and tumor
doubling and an / ratio of 10 for tumor,24 as done in the
Onishi study, the equivalent BED is 100.8 Gy10. The lack of
a dose-response relationship in the Nordic study may be
consistent with no evidence of a dose-response relationship
above a BED of 100 Gy10. Wulf et al.25 looked at the
dose-response curves in 92 lung lesions (36 NSCLC and 56
metastasis), and they demonstrated a dose-response curve
with a plateau near BED 100 Gy10 to the PTV margin at
which local control exceeds 95%. Additional literature re-
view by the same author suggests this to be consistent with a
range of reported studies,25 and improved local control with
BED more than 100 Gy10 was maintained in a further study
including four-dimensional dose modeling from the same
institution.26 Our observation of no statistical difference in
actuarial rates of local control between BED 100 and 180
Gy10 is consistent with this, suggesting that there may be no
large dose-response gain above 100 Gy10 to the PTV margin.
Furthermore, patients treated in our series with 50 Gy were
prescribed to the PTV margin by intensity modulated radia-
tion therapy using high-isodose prescription lines (97–100%)
and very homogeneous plans. Therefore, prescribing 50 Gy to
lower isodose lines would increase only the equivalent dose
and would be unlikely to result in lowering of local control.27
A challenge in applying the linear quadratic model to
SBRT is that it is most accurate for standard fractionated
radiation (1.8–4 Gy/fraction). Compared with experimen-
tally measured biologic data, the linear quadratic model
seems to overestimate delivered dose for hypofractionated
treatments characteristic of SBRT, suggesting the need for
better modeling.17,18 Such errors in estimating the equivalent
dose for hypofractionated radiation make comparisons be-
tween fractionation schedules difficult, especially when a
large variety of regimens are considered within a single
dataset. In light of this problem, a strength of our study is that
only two fractionation schedules were used, making the
biologic modeling of equivalent doses a much smaller factor
compared with studies comparing a wide range of fraction-
ation schedules converted to BED. Although we can make no
conclusions about BEDs less than 100 Gy10, our study does
suggest that the 180 Gy10 achieved by 60 Gy in three
fractions may not result in significantly better control than 50
Gy in five fractions (BED 100 Gy10).
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Dose-response relationships may also be related to
tumor size. Onimaru et al.28 described improved local control
and overall survival in IB tumors treated to 48 Gy compared
with 40 Gy in four fractions but found no such differences for
IA lesions. We observed no increased local control or overall
survival in IB patients treated to 60 Gy versus 50 Gy, again
suggesting that even for IB tumors the dose-response curve
may begin to plateau around a BED of 100 Gy10. An impor-
tant caveat to this is that our comparison included relatively
small tumors (in general 5 cm or less), whereas larger tumors
received other fractionation schedules, and thus no conclu-
sions can be drawn for a dose-response relationship for
tumors larger than 5 cm.
Because approximately one-third of our patients were
treated without histologic diagnosis (treated by radiographic
criteria, enlarging lesion on serial CT with a positive PET, or
increasing SUV on serial PET), we sought to verify that this
population had a natural history similar to those in whom
histologic diagnosis was attained. The statistically similar
survival of the patients with only radiographic diagnosis is
reassuring for our selection techniques and consistent with an
earlier report.29 However, there are clearly many confounding
variables between these groups. Although one would ideally
assess differences in local control by the method of diagnosis
to reduce the influence of comorbidities, we had only two
local failures and, therefore, chose to focus on survival. The
similar survival of these two groups suggests that our radio-
graphic criteria seem to be reasonable selection criteria in
patients whose biopsy is medically contraindicated or multi-
ply nondiagnostic.
Our nodal failure rate of 8% is consistent with prior
literature for PET-staged patients. Reported rates range from
7%, even in patients without pretreatment PET to as high as
25% in surgical or SBRT studies with frequent post-treatment
PET and long-term follow-up.1,9,30,31 This reinforces the use
of CT and PET for staging and supports the treatment of this
population to sites of only gross disease, thereby limiting
toxicity.
Our rate of distant metastasis is consistent with prior
literature ranging from 14 to 26%.1,9,32 Given the excellent
local control independent of the fractionation regimen in our
population, we did not expect to see differences in nodal or
distant failure, which are likely related to occult disease at the
time of treatment. Factors previously correlated with nodal
failure are degree of differentiation and tumor size.30 Distant
failure rates are also likely influenced by the degree of
pretreatment staging.
With no clear difference in local control by treatment
regimen, expected toxicity becomes critical in selecting the
SBRT dose. One patient in each dose group developed grade
2 radiation pneumonitis, which is consistent with prior series
with a low conformality index and small irradiated vol-
umes1,5,9–12,28,29,32,33 over a wide range of BEDs. Radiation
dose was not correlated with pulmonary toxicity or PFT
changes; however, all central tumors were treated with 50 Gy,
and so pulmonary toxicity may not be completely indepen-
dent of dose, particularly in central tumors. Treatment to
60–66 Gy in three fractions was noted to be associated with
grade 3 pulmonary complications in nearly half of all central
lesions treated in the Indiana University phase II study.10
Late chest wall toxicity is an increasingly recognized
complication of SBRT and has been reported in up to 10% of
patients when mild pain and asymptomatic rib fractures are
included.1,7–9,28 Two recent abstracts including asymptomatic
fractures suggest that some chest wall toxicity may occur
even more commonly in as many as 20 to 40% of patients
with peripheral tumors.20,21 Toxicity resolves spontaneously
in some patients.21 Chest wall toxicity occurred at a median
of 8 months after SBRT in our study. Toxicity was observed
if mild and was otherwise treated with nonsteroidal or nar-
cotic analgesics and gabapentin when more severe. Although
prior reports have included asymptomatic fractures, we scored
only chest wall pain. Toxicity was substantially higher in pa-
tients who received 60 Gy (18.4% versus 4.1% of peripheral
lesions). Of concern is that the median time to toxicity was not
substantially shorter than the median follow-up for the 60 Gy
group, suggesting that the disparity may increase with further
follow-up. No clear patient factors associated with toxicity
were identified. Dosimetric study is needed to determine
whether toxicity is purely a function of treatment dose or
whether it may be minimized by altering the treatment tech-
nique.
CONCLUSION
There was no difference in local control or overall
survival by dose or SBRT delivery method in our population
of medically inoperable stage I lung cancer patients. There
was an increased incidence of delayed chest wall toxicity in
the 60 Gy cohort. One may consider treating to only 50 Gy in
five fractions, particularly for large lesions near the chest
wall. Randomized data and longer follow-up are required for
a definitive conclusion.
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